ST. PETER HIV-Alcohol, Protein Biomarkers and Cardiovascular Disease Risk
英石。
基本信息
- 批准号:9349871
- 负责人:
- 金额:$ 19.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAlcohol consumptionAlcoholic CardiomyopathyAlcoholic beverage heavy drinkerAlcoholsBiochemicalBiological MarkersBiometryBrain natriuretic peptideCardiacCardiovascular DiseasesCaringCholineClinicalClinical TrialsCollaborationsCollectionComplementCoronary heart diseaseCytosineDataDietDiseaseEchocardiographyEnrollmentEquilibriumEventFoodFrequenciesFundingFutureGeneral PopulationHIVHIV InfectionsHealthHeart failureHeavy DrinkingInterventionIntervention StudiesIntestinesLeadLifeLinkMeasurementMeasuresMediatingMediationMorbidity - disease rateNatriuretic PeptidesNatureObservational StudyOrganOutcomeParticipantPathway interactionsPatient Self-ReportPatientsPersonsPharmacologyPopulationPositioning AttributePrimary PreventionProductionProteomicsPublishingQuestionnairesRandomized Clinical TrialsRandomized Controlled TrialsRecording of previous eventsRecruitment ActivityReportingResearchResearch InfrastructureResourcesRiskRisk FactorsRussiaSmokerStretchingStructureTestingVentricularalcohol abuse therapyalcohol use disorderbiomarker identificationcardiovascular disorder riskdata managementheart disease riskimprovedindexingmembermicrobialmicrobial genomemicrobiomemicrobiotamortalitynonhuman primatepeptide Bphosphatidylethanolprotein biomarkerssmoking cessationtreatment strategytrimethylaminetrimethyloxaminevarenicline
项目摘要
Heavy alcohol use among human immunodeficiency virus infected (HIV+) people is common and
associated with heart failure (HF) and coronary heart disease (CHD). An unexplored potential mechanism
for this association involves changes in intestinal microbial populations (dysbiosis), which occur with heavy
alcohol use or HIV infection. Dysbiosis may shift the balance of microbial genomes (microbiomes) to promote
increased trimethylamine N-oxide (TMAO) production. Increased TMAO is associated with cardiovascular
disease (CVD) events, including subclinical CHD and HF morbidity and mortality in the general population. Yet,
no published studies have assessed the link between alcohol and TMAO or TMAO and subclinical HF among
HIV+ people. We hypothesize that among HIV+ heavy drinkers, alcohol use is associated with higher levels of
TMAO, and that higher TMAO levels are associated with subclinical measures and biomarkers of HF. We will
test these hypotheses in ST. PETER HIV – CVD, an observational study that will be built on and complement
St. PETER HIV, a randomized clinical trial (U01AA020780; begins enrollment Winter 2017). The St. PETER
HIV clinical trial is testing the effects of varenicline vs. cytosine on simultaneous alcohol reduction and smoking
cessation among 400 HIV+ heavy drinkers (≥5 heavy drinking days in prior month) and daily smokers in St.
Petersburg, Russia. Major strengths of ST. PETER HIV - CVD are the existing complementary
resources/infrastructure of the St. PETER HIV clinical trial including:1) participant recruitment; 2) validated self-
report alcohol consumption; 3) biospecimen collection; 4) expertise and strong history of collaboration on
alcohol, HIV and CVD research of the U.S. and Russia team members undertaking this study. In ST. PETER
HIV – CVD, we propose to collect at baseline and 3 months the following new data: TMAO, echocardiography,
B-type natriuretic peptide (BNP; biomarker of ventricular stretching), phosphatidylethanol (PEth; alcohol
biomarker) and food frequency questionnaires. Echocardiography will be measured also at 6 months. With
these existing and new data, we will be uniquely positioned to complete the following aims:
AIM 1: To assess whether heavier alcohol use (Alcohol Use Disorders Identification Test, AUDIT≥20) is: a)
cross-sectionally and b) longitudinally associated with TMAO levels among HIV+ heavy drinkers;
AIM 2: To assess whether TMAO is associated with cardiac function and BNP in this population; and
AIM 3: To explore whether TMAO mediates the association of alcohol use and subclinical HF risk.
If confirmed, our hypotheses will identify a biomarker (TMAO) responsive to interventions that reduce alcohol-
related CVD risk in HIV+ heavy drinkers. Because heavy alcohol use interventions do not succeed in all,
developing new alcohol treatment strategies that reduce alcohol’s negative health impact among HIV+ people
are needed. The identification of biomarkers and the pathways they represent (e.g., dysbiosis) could result in
new targets for intervention studies and improve CVD risk prediction in HIV+ drinkers.
在人类免疫缺陷病毒感染者(HIV+)中大量饮酒是常见的,
与心力衰竭(HF)和冠心病(CHD)相关。一种未被探索的潜在机制
因为这种联系涉及肠道微生物群的变化(生态失调),这与重金属中毒有关。
酗酒或感染艾滋病毒。生态失调可能会改变微生物基因组的平衡,
增加的三甲胺N-氧化物(TMAO)产生。TMAO增加与心血管疾病有关
疾病(CVD)事件,包括一般人群中的亚临床CHD和HF发病率和死亡率。然而,
没有发表的研究评估酒精和TMAO或TMAO和亚临床HF之间的联系,
艾滋病毒阳性者。我们假设,在HIV+重度饮酒者中,饮酒与更高水平的
较高的TMAO水平与HF的亚临床指标和生物标志物相关。我们将
在圣彼得HIV - CVD中测试这些假设,这是一项观察性研究,
圣PETER HIV,一项随机临床试验(U 01 AA 020780; 2017年冬季开始入组)。圣彼得
HIV临床试验正在测试伐尼克兰与胞嘧啶对同时减少酒精和吸烟的影响
400名HIV+重度饮酒者(前一个月≥5个重度饮酒日)和每日吸烟者在St.
俄罗斯,彼得堡。圣彼得HIV - CVD的主要优势是现有的互补性
圣彼得HIV临床试验的资源/基础设施,包括:1)参与者招募; 2)经过验证的自我验证;
报告酒精消费; 3)生物标本采集; 4)专业知识和强大的合作历史,
酒精,艾滋病毒和CVD研究的美国和俄罗斯的团队成员进行这项研究。在圣彼得
HIV - CVD,我们建议在基线和3个月时收集以下新数据:TMAO,超声心动图,
B型利钠肽(BNP;心室伸展的生物标志物)、磷脂酰乙醇(PEth;酒精
生物标志物)和食物频率问卷。还将在6个月时测量超声心动图。与
这些现有的和新的数据,我们将处于独特的地位,以完成以下目标:
目的1:评估重度饮酒(酒精使用障碍识别测试,AUDIT≥20)是否:a)
B)与HIV+重度饮酒者的TMAO水平纵向相关;
目的2:评估TMAO是否与该人群的心功能和BNP相关;
目的3:探讨氧化三甲胺是否介导饮酒与亚临床心力衰竭风险之间的关系。
如果得到证实,我们的假设将确定一种对减少酒精的干预措施有反应的生物标志物(TMAO)-
HIV+重度饮酒者的CVD风险。因为酗酒的干预措施并不总是成功的,
制定新的酒精治疗策略,减少酒精对艾滋病毒阳性人群健康的负面影响
是必要的。生物标志物及其代表的途径的鉴定(例如,生态失调)可能导致
为干预研究提供新的目标,并改善HIV+饮酒者的CVD风险预测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW S FREIBERG其他文献
MATTHEW S FREIBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW S FREIBERG', 18)}}的其他基金
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
- 批准号:
10685513 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Administrative, Education, and Analytic Support Core
行政、教育和分析支持核心
- 批准号:
10304047 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
- 批准号:
10685704 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
- 批准号:
10304049 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Administrative, Education, and Analytic Support Core
行政、教育和分析支持核心
- 批准号:
10685508 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)
范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)
- 批准号:
10429901 - 财政年份:2018
- 资助金额:
$ 19.96万 - 项目类别:
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)
范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)
- 批准号:
10202711 - 财政年份:2018
- 资助金额:
$ 19.96万 - 项目类别:
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)
范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)
- 批准号:
9761561 - 财政年份:2018
- 资助金额:
$ 19.96万 - 项目类别:
ST. PETER HIV-Alcohol, Protein Biomarkers and Cardiovascular Disease Risk
英石。
- 批准号:
9770731 - 财政年份:2017
- 资助金额:
$ 19.96万 - 项目类别:
Immune function and the risk of cvd among HIV infected and uninfected veterans
HIV感染者和未感染者的免疫功能和CVD风险
- 批准号:
9268918 - 财政年份:2014
- 资助金额:
$ 19.96万 - 项目类别:
相似海外基金
Molecular mechanisms of carcinogenesis and symptoms associated with alcohol consumption
致癌的分子机制和饮酒相关症状
- 批准号:
23K05734 - 财政年份:2023
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The investigation of chronic alcohol consumption enhanced aging colon in elder mice and the mechanism of suppressed on aging colon tissues by sesame lignans continuous intake
长期饮酒促进老年小鼠结肠衰老的研究及持续摄入芝麻木脂素抑制结肠组织衰老的机制
- 批准号:
23K10904 - 财政年份:2023
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Internal Sources of Minority Stress and Alcohol Consumption
少数群体压力和饮酒的内部根源
- 批准号:
10742318 - 财政年份:2023
- 资助金额:
$ 19.96万 - 项目类别:
Characterizing the Relationship Between Alcohol Consumption and Neuron-Derived Exosomal MicroRNA Cargo in an Adolescent-Young Adult Twin Cohort
青少年双胞胎队列中酒精消耗与神经元衍生的外泌体 MicroRNA 货物之间关系的表征
- 批准号:
10452928 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Endocrine regulation of alcohol consumption and fear learning
饮酒和恐惧学习的内分泌调节
- 批准号:
10483780 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
The impact of friends sharing different modalities of alcohol-related social media content on alcohol consumption: A longitudinal examination of changes in content shared by social networks over time
朋友分享不同形式的酒精相关社交媒体内容对饮酒的影响:对社交网络分享内容随时间变化的纵向研究
- 批准号:
10534428 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
- 批准号:
10339931 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity
长期饮酒会导致自分泌运动因子水平升高,从而抑制抗肿瘤免疫力
- 批准号:
10370159 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
- 批准号:
10595096 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Technology-based assessments and intervention to reduce alcohol consumption and improve HIV viral suppression in the Florida Cohort
基于技术的评估和干预,以减少佛罗里达队列的饮酒量并改善艾滋病病毒抑制
- 批准号:
10707386 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别: